February 1, 2011 – The U.S. Food and Drug Administration has approved a Phase I clinical trial to test a new technology for treating critical limb ischemia (CLI). The Investigational Device Exemption (IDE) allows Arteriocyte to test its Magellan MAR01 technology.

February 1, 2011 – Despite the benefits of therapy with implantable cardioverter-defibrillators (ICDs), inappropriate shocks from the devices are common and place patients at a greater mortality risk. These were the conclusions drawn by a Dutch research team that examined the incidence, predictors and patient outcomes of inappropriate ICD shocks in a large, real-world patient population.

January 31, 2011 – Volcano Corp. said today the Superior Court of Massachusetts issued a decision ruling in favor of Volcano and its subsidiary Axsun Technologies Inc., and against LightLab Imaging Inc., on all of LightLab's remaining claims for intravascular optical coherence tomography (OCT) trade secret misappropriation.

February 1, 2011 – A self-anchoring aortic heart valve has received the CE mark. With the approval, the Perceval S Sutureless biological valve, by the Sorin Group, is now commercially available in Europe.

January 31, 2011 – Parental history of heart disease nearly doubles a person’s risk in all regions of the world, even after considering all other known risk factors of heart disease. The results come from a study published in the Feb. 1, 2011, issue of the Journal of the American College of Cardiology.

January 31, 2011 – The first successful transcatheter implantation of a 27 mm transapical aortic valve prosthesis has been completed. The procedure was performed by Hendrik Treede, M.D., at the University Heart Center Hamburg using JenaValve’s transcatheter aortic valve implantation (TAVI) system.

It was part of the company’s ongoing pivotal CE mark trial

January 31, 2011 – A new catheter used to treat coronary artery disease has received regulatory clearance in the United States and approval in Japan. The Trek and Mini-Trek systems, by Abbott, are used in angioplasty procedures and are designed to enable interventional cardiologists to open patients' narrowed coronary arteries.

The Trek system received the CE mark in May 2010.

January 31, 2011 – The U.S. Food and Drug Administration (FDA) has approved a system for accessing and delivering diagnostic, embolic and therapeutic materials into the peripheral vasculature. The Renegade HI-FLO Fathom Pre-Loaded System, by Boston Scientific, will be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer.

January 28, 2011 – The Civil Division of the U.S. Department of Justice (DOJ) filed a civil False Claims Act lawsuit against Boston Scientific, Guidant LLC and other entities seeking additional payments related to faulty implantable cardioverter defibrillators (ICDs).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now